Clinical genitourinary cancer最新文献

{"title":"The Influence of Chronic Kidney Disease on the Management of Upper Urinary Tract Cancer Following Radical Nephroureterectomy: A Nationwide Multi-Institutional Study.","authors":"Chih-Chin Yu, Steven K Huang, Wen-Hsin Tseng, Hung-Lung Ke, Wei-Ming Li, Chao-Hsiang Chang, Wen-Chi Chen, I-Hsuan Alan Chen, Jen-Tai Lin, Jen-Shu Tseng, Wun-Rong Lin, Jian-Hua Hong, Chao-Yuan Huang, Shian-Shiang Wang, Chuan-Shu Chen, Ian-Seng Cheong, Cheng-Huang Shen, Chung-You Tsai, Pai-Yu Cheng, Yuan-Hong Jiang, Yu Khun Lee, Chia-Chang Wu, Thomas Y Hsueh, Yung-Tai Chen, Hsu-Che Huang, Ting-En Tai, Wei Yu Lin, Po-Hung Lin, Chi-Wen Lo, Yao-Chou Tsai","doi":"10.1016/j.clgc.2025.102394","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102394","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the impact of chronic kidney disease (CKD) on oncological outcomes in patients with upper tract urothelial cancer (UTUC) undergoing radical nephroureterectomy (RNU) in Taiwan.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using data from the Taiwan UTUC Collaboration database. 1590 patients who underwent RNU for UTUC were included in the analysis. Patients were categorized into 2 groups: those with adequate renal function and those with preoperative CKD. Overlap weighting was employed to address potential biases and baseline imbalances between the groups. Multivariable Cox regression models were used to analyze overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS).</p><p><strong>Results: </strong>Preoperative CKD was significantly associated with poorer overall survival (HR, 1.372; 95% CI, 1.060-1.775; P = .016) compared to patients with adequate renal function. However, no significant association was observed between CKD and CSS or DFS. Further analysis revealed that patients with advanced CKD had a higher risk of UTUC-related death due to competing risks of non-UTUC-related mortality.</p><p><strong>Conclusions: </strong>Preoperative CKD in UTUC patients undergoing RNU emerged as the sole risk factor for an inferior OS, without impacting CSS and DFS.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102394"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis, Treatment and Survival From Penile Cancer: Real-World Data From the National Health Service England Between 2013 and 2020.","authors":"Karl H Pang, Hussain M Alnajjar, Asif Muneer","doi":"10.1016/j.clgc.2025.102393","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102393","url":null,"abstract":"<p><strong>Introduction: </strong>The NHS National Disease Registration Service (NDRS) collects and curate data on cancer diagnoses. We report data for patients diagnosed with penile cancer (PeCa) in England between 2013 and 2020.</p><p><strong>Patient and methods: </strong>Data were extracted from the NDRS \"Get Data Out\" database. The incidence per year, route to diagnosis (RTD), treatment modalities and overall survival were analyzed.</p><p><strong>Results: </strong>4,268 men were diagnosed with PeCa between 2013 and 2020. The number of diagnoses increased from 485 in 2013 to 635 in 2019 (30.9% increase). 2168 (50.8%) patients had stage I-II disease and 824 (19.3%) had stage III-IV disease. The stage was unknown in 1,276 (29.9%) cases. The majority were diagnosed through the 2-week-wait (2ww) referral pathway (n = 1072, 34.2%) or via GP referrals (n = 1083, 34.6%). 263 (8.4%) patients presented as emergencies, with this RTD being more common in men aged ≥70 years (P = .04) or men with stage III-IV (P = .01). The most common treatment modality was surgery alone (n = 3,391, 79.5%). 56 (1.3%) men had radiotherapy and/or chemotherapy alone, which was more common in stage III-IV disease. At 12, 24 and 60 months, overall survival across all years was 86.3%, 77.6% and 63.8% respectively. Survival remained relatively stable over time. Patients aged ≥70 years (P < .0001) or with stage III-IV (P < .0001) had poorer survival.</p><p><strong>Conclusion: </strong>The NDRS provides valuable data on the rising incidence of PeCa, RTD, treatment and survival in England. Most of the patients were diagnosed through the 2ww or GP referral routes. Surgery was the primary treatment modality and survival remained stable over time.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102393"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of miR-181a-5p and its Target Genes in the Progression of Clear Cell Renal Cell Carcinoma and Association With the Immune Microenvironment.","authors":"Huaxi Liu, Guanfeng Luo, Bei Xie, Meilin Chen, Penghui Xie, Xiaoshan Zhao, Yanting You, Xiaomin Sun","doi":"10.1016/j.clgc.2025.102390","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102390","url":null,"abstract":"<p><strong>Background: </strong>Clear cell renal cell carcinoma (ccRCC) is one of the most predominant pathological types of renal cell carcinoma (RCC), with a high metastatic rate and poor prognosis. There is growing appreciation that miR-181a-5p plays a crucial role in various cancers, but the relevance of miR-181a-5p to disease progression in ccRCC and its mechanism of action in ccRCC remain poorly reported in detail. This study purposed to explore new biomarkers related to the prognosis of ccRCC and to uncover their potential mechanisms in influencing ccRCC progression.</p><p><strong>Methods: </strong>The dbDEMC and GEO databases were used to screen differential miRNAs and differential genes in ccRCC, respectively. KEGG pathway analysis was performed to further search for differential genes in ccRCC. The miRWalk database was used to predict target genes of miR-181a-5p. The miR-181a-5p and its target genes expression, clinicopathological correlation, prognosis analysis, and immune infiltration correlation were performed in the data obtained from TCGA. STRING database was performed to construct a PPI network of the target genes of miR-181a-5p and immune-related genes of ccRCC from TISIBD database. In vitro experiments were conducted to verify the effect of miR-181a-5p on the growth, invasion and migration of ccRCC cells and to verify the target genes of miR-181a-5p.</p><p><strong>Results: </strong>As a differential miRNA of ccRCC, miR-181a-5p is significantly up-regulated in ccRCC patients and has a high diagnostic accuracy. High expression of miR-181a-5p is related to poor progress free interval (PFI). KIT, MECOM, COL4A6, EGF, and MAPK10 are the target genes of miR-181a-5p, which are significantly down-regulated in ccRCC patients and have high diagnostic accuracy. Low expression of these genes is associated with disease progression and poor prognosis of ccRCC. In addition, miR-181a-5p and its target genes were found to be associated with the immune infiltration of ccRCC. In vitro experiments proved that miR-181a-5p promote the growth, invasion and migration of ccRCC cells, and it was found that COL4A6, EGF, and MAPK10 are more likely to be the target genes of miR-181a-5p.</p><p><strong>Conclusions: </strong>MiR-181a-5p may work together with its target genes to affect tumor-induced immune cell infiltration, and thus affect ccRCC. MiR-181a-5p and its target genes, such as EGF and MAPK10, may be novel prognostic markers and therapeutic targets for ccRCC patients.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102390"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Survival Outcomes of Partial Versus Radical Nephrectomy: Cause-Specific and Time-Dependent Effects.","authors":"Yuki Kohada, Hiroyuki Shikuma, Keisuke Goto, Kosuke Akiyama, Mitsuru Kajiwara, Shinji Matsuzaki, Akira Fujita, Kensuke Nishida, Ryo Tasaka, Shunsuke Miyamoto, Kohei Kobatake, Yohei Sekino, Hiroyuki Kitano, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata","doi":"10.1016/j.clgc.2025.102391","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102391","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the prognosis of radical nephrectomy (RN) and partial nephrectomy (PN) in patients with localized renal cell carcinoma (RCC), with particular consideration of cause-specific mortality and time-dependent effects on real-world survival outcomes.</p><p><strong>Patients and methods: </strong>This multicenter, retrospective study included patients with localized RCC who underwent RN or PN; 1:1 propensity score matching was conducted to minimize selection bias in the nonrandom assignment of patients to the PN and RN groups. Overall survival (OS), cancer-specific mortality (CSM), and other-cause mortality (OCM) were evaluated in patients who underwent RN or PN using conditional survival (CS) analysis.</p><p><strong>Results: </strong>In total, 802 patients were included in the RN and PN groups (401 patients in each). The RN group had a significantly poorer OS than the PN group (P = .031). CS analysis indicated that neither the RN nor the PN groups had significantly enhanced survival rates over extended survival periods. The CS rate was consistently higher in the PN group than in the RN group at all time points during follow-up. Only the conditional cumulative incidence of OCM in the RN group was consistently high during the follow-up period, but that of OCM in the PN group and CSM in these groups remained low, irrespective of the length of survival.</p><p><strong>Conclusion: </strong>PN was associated with better OS than RN in patients with localized RCC. CS analysis revealed this was attributed to a consistently high rate of OCM in the RN group during the follow-up period.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102391"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144669113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radical Surgery Compared to Bladder-Preserving Approaches for Limited Stage Small-Cell Bladder Cancer: Systematic Review and Meta-Analysis.","authors":"András Kubik, Isabel Pinto Amorim das Virgens, Nóra Varga, Anett Szabó, Attila Keszthelyi, Péter Fehérvári, Péter Hegyi, Nándor Ács, Péter Nyirády, Tibor Szarvas","doi":"10.1016/j.clgc.2025.102389","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102389","url":null,"abstract":"<p><strong>Background and objective: </strong>Small-cell bladder cancer (SCBC) is an aggressive and rare malignancy for which there is no clear optimal treatment strategy. This systematic review and meta-analysis aimed to compare the median overall survival (OS) of patients with limited-stage (LS) SCBC treated with either cystectomy-based multimodal therapy (CBMMT) or radiation-based multimodal therapy (RBMMT).</p><p><strong>Methods: </strong>A comprehensive search of PUBMED, Embase, and Scopus databases was performed for studies published before January 2024 according to the PRISMA guidelines. Studies have assessed LS-SCBC disease and provided survival data for subgroups of patients undergoing radical surgery or bladder-preserving approaches to be deemed eligible. Data extraction and quality assessment were independently conducted by 2 authors.</p><p><strong>Key findings and limitations: </strong>Five studies comprising 1041 patients were analyzed. The pooled median OS for patients receiving RBMMT was 34.6 months (95% CI, 25.5-43.7), compared to 29.7 months (95% CI, 18.2-41.1) for those undergoing CBMMT. The main limitations are the retrospective nature of the included studies and the potential bias.</p><p><strong>Conclusions and clinical implications: </strong>This meta-analysis indicates that RBMMT may provide comparable outcomes to CBMMT in LS-SCBC patients, supporting the consideration of bladder-preserving approaches in selected cases. RBMMT may offer a potential clinical benefit in terms of organ preservation for appropriately selected patients, although survival differences were not statistically significant.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102389"},"PeriodicalIF":0.0,"publicationDate":"2025-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns and Survival in People With Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States.","authors":"Amit D Raval, Guifang Chen, Matthew J Korn, Andreas Bernthaler, Niculae Constantinovici, Stephen J Freedland","doi":"10.1016/j.clgc.2025.102386","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102386","url":null,"abstract":"<p><strong>Purpose: </strong>To examine treatment patterns and survival in people with metastatic castration-resistant prostate cancer (mCRPC) previously progressing from metastatic hormone-sensitive prostate cancer (mHSPC) in the United States.</p><p><strong>Methods: </strong>People diagnosed with mCRPC between January 1, 2020-June 30, 2023 were retrospectively identified in the ConcertAI NLP360™ electronic medical records (EMR) database. Inclusion criteria were prior diagnosis of mHSPC and ≥1 EMR encounter ≥12 months pre-mCRPC and ≥6 months post-mCRPC.</p><p><strong>Results: </strong>Among 609 people identified, the most common prior treatment for mHSPC was androgen deprivation therapy (ADT) alone (53%); others included ADT plus abiraterone (ABI; 19%), ADT plus a non-ABI androgen receptor pathway inhibitor (ARPI; 18%) and ADT plus docetaxel (10%). Overall, the most common first-line (1L) therapies for mCRPC were a non-ABI ARPI (37%; most commonly enzalutamide [24%]), ABI (25%), and chemotherapy (22%). These were also the most common 1L mCRPC therapies for those receiving ADT alone or ADT plus docetaxel for mHSPC. Among those who received ADT plus ABI or a non-ABI ARPI for mHSPC, 50% and 40%, respectively, also received an ARPI 1L for mCRPC. 1L chemotherapy for mCRPC was more common following ADT combination regimens (24%-41%) than ADT alone (12%) for mHSPC. Median real-world overall survival was 27.2 months from mCRPC diagnosis and 20.8 months from 1L therapy.</p><p><strong>Conclusion: </strong>Back-to-back ARPI use from mHSPC to mCRPC is common in current clinical practice and survival remains <3 years. Alternative mCRPC treatments, such as intensified combination regimens beyond androgen receptor targeting, require exploration to improve survival in mCRPC.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102386"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a multidisciplinary tumour board (MTB) on treatment decision making for patients with renal cell carcinoma (RCC): 5-year data analysis","authors":"L. Brink, A. Ruiter, B. Lagerveld, N. Graafland, A. Bex, H. Beerlage, R.J.M. van Moorselaar, P. Zondervan","doi":"10.1016/j.clgc.2024.01.021","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.01.021","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"327 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139822790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study","authors":"Margaret Meagher, Kylie M. Morgan, Leah N. Deshler, Dhruv Puri, Kit Yuen, Aditya Bagrodia, Brent Rose, Tyler F Stewart, A. Salmasi","doi":"10.1016/j.clgc.2024.02.006","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.02.006","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"76 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139887499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic urothelial carcinoma: A single-centre retrospective study from 2004 to 2021.","authors":"Jose C. Tapia, Freya Bosma, J. Gavira, Sofia Sanchez, Maria Alejandra Molina, J. Sanz-Beltran, Cristina Martín-Lorente, G. Anguera, Pablo Maroto","doi":"10.1016/j.clgc.2024.01.019","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.01.019","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139815806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of Cystatin C-Based Sarcopenia Index in Patients Undergoing Surgery for Renal Tumors","authors":"S. Yajima, Y. Nakanishi, Ryo Andy Ogasawara, Naoki Imasato, Kohei Hirose, Sao Katsumura, M. Kataoka, H. Masuda","doi":"10.1016/j.clgc.2024.02.002","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.02.002","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"56 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139829352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}